Skip to main content

Table 2 Summary of MOS-HIV physical and mental health summary scores in NNRTI clinical trials

From: Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies

Citation

Treatment/dosing regimen

Follow-up period

Physical health summary scores

Mental health summary scores

Baseline

Follow-up

Significance

Baseline

Follow-up

Significance

Mean (SD)

Mean

Over time

Between groups

Mean (SD)

Mean

Over time

Between groups

Randomized controlled trials

Chang et al. (2007)

Intervention: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to tapes with instructions to elicit the relaxation response via earphones, followed by soft music played in the clinic

4 weeks

57.5 (21.1)

61.3

N

N

57.5 (17.0)

62.9

Y

N

8 weeks

62.7

N

N

62.8

N

N

12 weeks

65.6

Y

N

68.1

Y

N

Control: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to soft music played in the clinic

4 weeks

62.0 (21.4)

66.7

N

N

64.1 (17.9)

71.0

Y

N

8 weeks

66.4

N

N

69.5

N

N

12 weeks

65.7

N

N

70.7

N

N

Bucciardini et al. (2007)

Didanosine + stavudine + efavirenz

1 year

50 (11)

54.7

N

N

49 (10)

53.0

N

N

2 years

 

54.9

N

N

 

50.4

N

N

3 years

 

54.9

N

N

 

49.5

N

N

Didanosine + stavudine + nelfinavir

1 year

46 (13)

46.7

N

N

48 (10)

50.8

N

N

2 years

 

49.2

N

N

 

51.5

N

N

3 years

 

50.9

N

N

 

53.5

N

N

Didanosine + stavudine + efavirenz + nelfinavir

1 year

48 (12)

50.0

N

N

50 (9)

50.0

N

N

2 years

48.1

N

N

49.5

N

N

3 years

50.0

N

N

53.4

N

N

Huang et al. (2008)

Tipranavir + ritanovir

48 weeks

48.0 (11.3)

48.2

NM

N

47.8 (10.5)

49.2

NM

N

Boosted comparitor protease inhibitor

48 weeks

47.1 (10.9)

46.8

NM

N

46.9 (10.3)

48.6

NM

N

Lafaurie et al. (2008)

Maintenance of a stable protease inhibitor-containing regimen

48 weeks

NR

−1.04

NM

N

NR

0.00

NM

N

Switch to efavirenz + didanosine + emtricitabine once-daily

48 weeks

NR

−1.76

NM

N

NR

1.01

NM

N

Sprinz et al. (2006)

Immediate substitution with lopinavir/ritonavir 400/200 mg twice daily

4 weeks

49.44

52.06

Y

Y

46.7

50.79

Y

Y

8 weeks

 

52.38

Y

Y

 

51.34

Y

Y

Deferred (week 4) substitution with lopinavir/ritonavir 400/100 mg twice daily

4 weeks

50.32

49.71

N

Y

48.25

48.03

N

Y

8 weeks

51.12

N

Y

50.02

Y

Y

Nuesch et al. (2009)

Continuous treatment

24 weeks

53.8 (6.6)

52.7

N

N

51.7 (7.6)

52.7

Y

Y

48 weeks

52.5

N

N

52.5

Y

Y

CD4-guided scheduled treatment interruption (CD4 threshold of 350 cells/μL for interruption/re-initiation of ARV therapy)

24 weeks

54.4 (6.3)

53.2

N

N

49.1 (8.3)

48.1

Y

Y

48 weeks

53.2

N

N

49.5

Y

Y

Powers et al. (2006)

Intermittent treatment (7 cycles of 4 weeks off/8 weeks on HAART)

4 weeks

54.2 (8.3)

54.2

N

Y

54.0 (8.8)

53.56

N

Y

12 weeks

 

55.55

N

Y

 

57.45

Y

Y

40 weeks

 

54.76

N

Y

 

57.22

Y

Y

Continuous treatment (continue regimen for 22 weeks)

4 weeks

53.0 (11.5)

53.27

N

Y

53.8 (15.7)

53.36

N

Y

12 weeks

 

52.97

N

Y

 

57.25

N

Y

40 weeks

 

54.00

N

Y

 

57.02

N

Y

Wu et al. (2006)

Disease Management Assistance System + education

6 months

45.7 (11.0)

44.2

NR

Y

49.2 (10.3)*

49.5

NR

N

Education only

6 months

41.2 (12.7)

47.0

NR

Y

40.7 (12.4)*

44.9

NR

N

Non-randomized controlled trials

Shalit et al. (2007)

Enfuvirtide + ARTs

12 weeks

NR

2.21

Y

N/A

NR

2.91

Y

N/A

Levine et al. (2008)

Epoetin alfa + iron supplementation (in addition to current ART regimen)

MPD1

38.5 (12.0)

43.0

N

N/A

42.4 (11.2)

47.8

N

N/A

24 weeks

43.5

Y

N/A

47.5

Y

N/A

Stangl et al. (2007)

HAART and weekly home visits by study staff that re-supplied HAART and other drugs, conducted a pill count, and assessed participants’ health

3 months

39.2 (9.8)

50.6

Y

N/A

40.0 (11.2)

50.2

Y

N/A

6 months

53.0

Y

N/A

53.0

Y

N/A

9 months

53.6

Y

N/A

54.2

Y

N/A

12 months

54.2

Y

N/A

54.2

Y

N/A

  1. *significant difference in baseline scores (P=0.01).